InterDigital also announces fourth quarter results as company plots future growth from Technicolor acquisition
Eastern District of Texas jury rules that patent royalty rates offered to the Taiwanese company were FRAND and that the comparable licensing model used to calculate them was correct
Reviews challenge validity of patents owned by Opiant Pharmaceuticals relating to Narcan brand of naloxone as price of treatments rises
Supported by a healthy balance sheet, Marc Booth says the firm plans on a higher volume of smaller deals with three new areas identified for future growth
Congressional action is the only way to solve the uncertainty on section 101 of the US patent statute, argues Aaric Eisenstein of Personalised Media Communications
In a Delaware case Boehringer Ingelheim accuses the Illinois company of improper conduct in deliberately constructing a patent thicket to protect against generic versions of its blockbuster drug.
With new guidelines set to reshape patent examination, the USPTO head makes the case for revisiting subject matter precedent
The company behind Tik Tok bought out much of a struggling smartphone maker’s patent portfolio in January. USPTO assignments from last week show what assets Beijing-based ByteDance came away with
Senior decision makers from a wide range of companies are already confirmed to attend as demand for tickets exceeds the rate for last year's sell-out event in San Francisco
The settlement deal ends litigation by the Singapore company’s ZiiLabs unit against Nvidia, and will net shareholders around $17.5 million
Coherus launched Delaware action against Amgen in what is likely to become an increasingly familiar life sciences litigation scenario.
PTAB reforms help fuel a miraculous rise up the latest International IP Index, but a recent Federal Circuit decision on eligibility highlights the serious challenges that remain - especially for life sciences companies
If the Commission and Apple are successful in rewriting the rules for chipmaker's licensing arm beware of unintended consequences that reduce choice and harm consumers, expert analyst states
The Federal Circuit’s precedential judgment in Supernus Pharmaceuticals v Iancu is good news for rights holders – especially those in life sciences
Latest report suggests that result of a strategic review will see the company's product and IP arms separate, but current courtroom tussle with Comcast means the timing is not great